Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer

PURPOSE: The ASCENT trial demonstrated the efficacy of sacituzumab govitecan for the treatment of advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of receiving sacituzumab govitecan compared with standard of care chemotherapy from the Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Yitian, Chai, Qingqing, Tao, Wenqi, Liao, Yahui, Liu, Xiaoyan, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947096/
https://www.ncbi.nlm.nih.gov/pubmed/36780838
http://dx.doi.org/10.1016/j.breast.2023.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947096/
https://www.ncbi.nlm.nih.gov/pubmed/36780838
http://dx.doi.org/10.1016/j.breast.2023.02.003

Ejemplares similares